Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases.
暂无分享,去创建一个
[1] T. Olsson,et al. Polymorphism analysis suggests that the gelatinase B gene is not a susceptibility factor for multiple sclerosis , 2000, Journal of Neuroimmunology.
[2] A. Gnasso,et al. Genetic variation in human stromelysin gene promoter and common carotid geometry in healthy male subjects. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[3] A M Zeiher,et al. Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. , 2000, Circulation research.
[4] S. Loening,et al. Matrix‐metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma , 2000, International journal of cancer.
[5] I. Ebihara,et al. Elevation of Serum Levels of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-1 and Type IV Collagen, and Plasma Levels of Metalloproteinase-9 in Polycystic Kidney Disease , 2000, American Journal of Nephrology.
[6] A. Clowes,et al. Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodeling in the injured rat carotid artery. , 1999, Circulation research.
[7] H Yonas,et al. Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm. , 1999, Stroke.
[8] H. Kuivaniemi,et al. Genetic analysis of MMP3, MMP9, and PAI-1 in Finnish patients with abdominal aortic or intracranial aneurysms. , 1999, Biochemical and biophysical research communications.
[9] A. Henney,et al. Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2–13.1 , 1999, Human Genetics.
[10] T. Seifert,et al. Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis , 1999, Journal of Neuroimmunology.
[11] Y. Nakamura,et al. Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region. , 1999, Cancer research.
[12] T. K. Hunt,et al. Impaired wound contraction in stromelysin-1-deficient mice. , 1999, Annals of surgery.
[13] K. Sirotkin,et al. dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. , 1999, Genome research.
[14] D. Pinkel,et al. The Stromal Proteinase MMP3/Stromelysin-1 Promotes Mammary Carcinogenesis , 1999, Cell.
[15] Y. Sasaguri,et al. Shortened microsatellite d(CA)21 sequence down‐regulates promoter activity of matrix metalloproteinase 9 gene , 1999, FEBS letters.
[16] L. Matrisian,et al. Measurement of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Blood and Tissues: Clinical and Experimental Applications , 1999, Annals of the New York Academy of Sciences.
[17] A. Nagano,et al. Measurement of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in patients with knee osteoarthritis: comparison with generalized osteoarthritis. , 1999, Rheumatology.
[18] C. Iwai,et al. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. , 1999, Circulation.
[19] A. Henney,et al. Human stromelysin gene promoter activity is modulated by transcription factor ZBP‐89 , 1999, FEBS letters.
[20] A. Evans,et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. , 1999, Circulation.
[21] A. Zwinderman,et al. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. , 1999, The American journal of cardiology.
[22] E. Mochan,et al. Identification of a Cytokine-induced Repressor of Interleukin-1 Stimulated Expression of Stromelysin 1 (MMP-3)* , 1999, The Journal of Biological Chemistry.
[23] J. Rutter,et al. Transcriptional repression of the human collagenase-1 (MMP-1) gene in MDA231 breast cancer cells by all-trans-retinoic acid requires distal regions of the promoter , 1999, British Journal of Cancer.
[24] S. Zucker,et al. Increased serum stromelysin-1 levels in systemic lupus erythematosus: lack of correlation with disease activity. , 1999, The Journal of rheumatology.
[25] W. Pearce,et al. Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms. , 1999, Journal of vascular surgery.
[26] T. Iizasa,et al. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] J. D’Armiento,et al. Epidermal expression of collagenase delays wound-healing in transgenic mice. , 1998, The Journal of investigative dermatology.
[28] J. Gusella,et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. , 1998, Cancer research.
[29] L. Brooks,et al. A DNA polymorphism discovery resource for research on human genetic variation. , 1998, Genome research.
[30] J. Hardy,et al. Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease. , 1998, Human molecular genetics.
[31] T. Ueno,et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. , 1998, Journal of the American College of Cardiology.
[32] P. Talmud,et al. The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lopid Coronary Angiography Trial. , 1998, Atherosclerosis.
[33] F. Pasquier,et al. A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease. , 1998, Human molecular genetics.
[34] M. Fini,et al. Regulation of Matrix Metalloproteinase Gene Expression , 1998 .
[35] H. Nagase. Stromelysins 1 and 2 , 1998 .
[36] J. Woessner,et al. The Matrix Metalloproteinase Family , 1998 .
[37] J. Morris,et al. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia , 1998, Nature Genetics.
[38] S. Loening,et al. Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase‐1 and the complex of metalloproteinase‐1/tissue inhibitor in plasma of patients with prostate cancer , 1997, International journal of cancer.
[39] P. Libby,et al. Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. , 1997, Circulation.
[40] Y. Kodera,et al. Plasma concentration of matrix metalloproteinase 9 in gastric cancer , 1997, The British journal of surgery.
[41] M. Diaz-Meco,et al. Cross-talk between Different Enhancer Elements during Mitogenic Induction of the Human Stromelysin-1 Gene* , 1996, The Journal of Biological Chemistry.
[42] A. Henney,et al. Progression of Coronary Atherosclerosis Is Associated with a Common Genetic Variant of the Human Stromelysin-1 Promoter Which Results in Reduced Gene Expression* , 1996, The Journal of Biological Chemistry.
[43] M J Davies,et al. Acute coronary thrombosis--the role of plaque disruption and its initiation and prevention. , 1995, European heart journal.
[44] A D Roses,et al. Apolipoprotein E and Alzheimer disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[45] D. Steed,et al. Characterization of a dinucleotide repeat in the 92 kDa type IV collagenase gene (CLG4B), localization of CLG4B to chromosome 20 and the role of CLG4B in aortic aneurysmal disease , 1995, Annals of human genetics.
[46] A. Henney,et al. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. , 1994, British heart journal.
[47] S. Zucker,et al. Elevated plasma stromelysin levels in arthritis. , 1994, The Journal of rheumatology.
[48] P. Libby,et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.
[49] M. Reidy,et al. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. , 1994, Journal of vascular surgery.
[50] H. Nagase,et al. Identification of matrix metalloproteinases 3 (stromelysin-1) and 9 (gelatinase B) in abdominal aortic aneurysm. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[51] L. Matrisian,et al. Structure and expression of the human gene for the matrix metalloproteinase matrilysin. , 1994, The Journal of biological chemistry.
[52] H. Birkedal‐Hansen,et al. Matrix metalloproteinases: a review. , 1993, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.
[53] A. Henney,et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[54] L. Matrisian,et al. Metalloproteinases and their inhibitors in matrix remodeling. , 1990, Trends in genetics : TIG.
[55] M. Karin,et al. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor , 1987, Cell.
[56] R. Mahley,et al. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. , 1982, The Journal of biological chemistry.